these findings suggest that chronic oral administration of cholestyramine to patients with ulcerative colitis who are receiving salicylazosulfapyridine could result in a significant reduction in the absorption and metabolism of the drug and hence , in its therapeutic efficacy .
C0009324
ulcerative colitis
C0036078
salicylazosulfapyridine